Regulus Therapeutics (NASDAQ:RGLS) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a report published on Friday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other brokerages have also recently weighed in on RGLS. Needham & Company LLC restated a hold rating on shares of Regulus Therapeutics in a research report on Tuesday, August 13th. Wedbush restated a hold rating and issued a $1.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Finally, ValuEngine upgraded Regulus Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Regulus Therapeutics currently has an average rating of Hold and a consensus target price of $1.08.

Shares of RGLS stock opened at $0.56 on Friday. Regulus Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $4.08. The stock has a market cap of $11.87 million, a P/E ratio of -0.10 and a beta of 1.90. The business has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $1.08.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.24. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 396.84%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $2.50 million. Analysts forecast that Regulus Therapeutics will post -2.04 EPS for the current year.

A number of institutional investors have recently bought and sold shares of RGLS. NEA Management Company LLC increased its position in Regulus Therapeutics by 124.1% during the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock worth $2,566,000 after purchasing an additional 1,136,704 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $1,389,000. Samsara BioCapital LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $1,131,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $568,000. Finally, Virtu Financial LLC purchased a new stake in Regulus Therapeutics during the 1st quarter worth about $68,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

See Also: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Family Management Corp Acquires 431 Shares of Mcdonald’s Corp
Family Management Corp Acquires 431 Shares of Mcdonald’s Corp
Family Management Corp Increases Stock Holdings in Nuveen Arizona Premium Income Mun Fd
Family Management Corp Increases Stock Holdings in Nuveen Arizona Premium Income Mun Fd
Family Management Corp Has $383,000 Stock Holdings in Invesco Variable Rate Preferred ETF
Family Management Corp Has $383,000 Stock Holdings in Invesco Variable Rate Preferred ETF
Family Management Corp Sells 850 Shares of Bristol-Myers Squibb Co
Family Management Corp Sells 850 Shares of Bristol-Myers Squibb Co
CPV Partners LLC Buys New Holdings in Laureate Education Inc
CPV Partners LLC Buys New Holdings in Laureate Education Inc
Family Management Corp Increases Stake in Blackrock Muniholdings New York Qulty Fd
Family Management Corp Increases Stake in Blackrock Muniholdings New York Qulty Fd


© 2006-2019 Ticker Report